Fibroblast growth factor receptor 1 amplification is a common event in squamous cell carcinoma of the head and neck

Modern Pathology

Volumn 26, Issue 10, 2013, Pages 1298-1306

  Göke, Friederike ^a,b   Bode, Maike ^a,b   Franzen, Alina ^a,b   Kirsten, Robert ^b   Goltz, Diane ^a   Göke, Antonia ^b   Sharma, Rakesh ^b   Boehm, Diana ^b   Vogel, Wenzel ^b   Wagner, Patrick ^c   Lengerke, Claudia ^d   Kristiansen, Glen ^a   Kirfel, Jutta ^a   Van Bremen, Tobias ^a   Bootz, Friedrich ^a   Heasley, Lynn E ^e   Schröck, Andreas ^a   Perner, Sven ^a,b  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c Winchester Medical Center   (United States)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e UNIVERSITY OF COLORADO   (United States)

Author keywords

Amplification; Biomarker; Fibroblast growth factor receptor 1; Head and neck squamous cell carcinoma; HPV

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 1; FORMALDEHYDE; NICOTINE; PARAFFIN; PROTEIN P16;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CANCER PATIENT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE TARGETING; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIMARY TUMOR; PRIORITY JOURNAL; RECURRENT DISEASE; TUMOR RECURRENCE; VIRUS DETECTION; WART VIRUS;

AGED; CARCINOMA, SQUAMOUS CELL; FEMALE; GENE AMPLIFICATION; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; TUMOR MARKERS, BIOLOGICAL;

EID: 84885019152     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2013.58     Document Type: Article

References (23)

1. Beroukhim R, Mermel CH, Porter D, et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010;463: 899-905.
2. Frohling S, Dohner H. Chromosomal abnormalities in cancer. N Engl J Med 2008;359: 722-734.
3. Weir B, Zhao X, Meyerson M. Somatic alterations in the human cancer genome. Cancer Cell 2004;6: 433-438.
4. Bearz A, Berretta M, Lleshi A, et al. Target therapies in lung cancer. J Biomed Biotechnol 2011;2011: 921231.
5. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27: 1227-1234.
6. Sandler A, Gray R, Perry MC, et al. Paclitaxel- carboplatin alone or with bevacizumab for non-smallcell lung cancer. N Engl J Med 2006;355: 2542-2550.
7. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-smallcell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11: 121-128.
8. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-smallcell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009;373: 1525-1531.
9. Wagner PL, Perner S, Rickman DS, et al. In situ evidence of KRAS amplification and association with increased p21 levels in non-small cell lung carcinoma. Am J Clin Pathol 2009;132: 500-505.
10. Wesche J, Haglund K, Haugsten EM. Fibroblast growth factors and their receptors in cancer. Biochem J 2011;437: 199-213.
11. Powers CJ, McLeskey SW, Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 2000;7: 165-197.
12. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010;10: 116-129.
13. Turner N, Pearson A, Sharpe R, et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 2010;70: 2085-2094.
14. Weiss J, Sos ML, Seidel D, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010;2: 1-7.
15. Dutt A, Ramos AH, Hammerman PS, et al. Inhibitorsensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One 2011;6:e20351.
16. Reis-Filho JS, Simpson PT, Turner NC, et al. FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin Cancer Res 2006;12: 6652-6662.
17. Marshall ME, Hinz TK, Kono SA, et al. Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells. Clin Cancer Res 2011;17: 5016-5025.
18. Goeke F, Franzen A, Menon R, et al. Rationale for treatment of metastatic squamous cell carcinoma of the lung using FGFR Inhibitors. Chest 2012;142: 1020-1026.
19. Freier K, Schwaenen C, Sticht C, et al. Recurrent FGFR1 amplification and high FGFR1 protein expression in oral squamous cell carcinoma (OSCC). Oral Oncol 2007;43: 60-66.
20. Perner S, Wagner PL, Soltermann A, et al. TTF1 expression in non-small cell lung carcinoma: association with TTF1 gene amplification and improved survival. J Pathol 2009;217: 65-72.
21. Syrjanen K, Vayrynen M, Castren O, et al. Morphological and immunohistochemical evidence of human papilloma virus (HPV) involvement in the dysplastic lesions of the uterine cervix. Int J Gynaecol Obstet 1983;21: 261-269.
22. Chaturvedi AK, Engels EA, Anderson WF, et al. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 2008;26: 612-619.
23. Schlecht NF. Prognostic value of human papillomavirus in the survival of head and neck cancer patients: an overview of the evidence. Oncol Rep 2005;14: 1239-1247.